

OHSU Health Services Injectable Medication Post-Service Claims Edits Program

In collaboration with MagellanRx, the post-service, pre-payment claims edits program monitors and promotes appropriate use, safety, and cost effectiveness of injectable and infused medications given in a professional office, home, or outpatient setting. Claims are reviewed for appropriate frequency, correct units, and eligible diagnosis codes based on FDA label and drug compendia approved uses.

Prior authorization criteria *do not apply* for these medications. If the services billed do not meet the guidelines, the claims will be subject to review and potentially disallowed. The program is limited to the following injectable and/or infusion medications:

Effective April 1, 2020	
Procedure code	Brand name
J0717	Cimzia
J0185	Cinvanti
J9217	Eligard
J1453	Emend
J9395	Faslodex
J9201	Gemzar
J1950	Lupron Depot
J3315	Trelstar Depot
J9225	Vantas
A9606	Xofigo
Q5101	Zarxio
J9202	Zoladex
Effective July 1, 2020	
Procedure code	Brand name
A9699, C9408, A9590, A4641, A9699	Azedra
A9517	HICON
A9513	Lutathera
A9600	Metastron
A9604	Quadramet
A9543	Zevalin
Effective August 1, 2021	
J1952	Camcevi

This list is subject to change. Updates will be posted to this page as the program is expanded.